Tourmaline Bio(TRML) - 2024 Q2 - Quarterly Results

Exhibit 99.1 TOURMALINE Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights – First patient dosed in May 2024 in Phase 2 TRANQUILITY trial evaluating pacibekitug (TOUR006) in patients with high cardiovascular risk – – On track to initiate a pivotal Phase 3 trial evaluating pacibekitug delivered subcutaneously every 8 weeks as first-line treatment for Thyroid Eye Disease (TED) in the second half of 2024 – – Added to the Russell 2000® Index and the broad-market Russell ...